YCBD:NYE-cbdMD Inc (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 0.57

Change

0.00 (0.00)%

Market Cap

USD 2.14M

Volume

6.40K

Analyst Target

USD 5.20
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-08 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

N/A

USD 85.62B
RDY Dr. Reddy’s Laboratories Ltd..

N/A

USD 63.63B
TAK Takeda Pharmaceutical Co Ltd A..

N/A

USD 44.45B
HLN Haleon plc

N/A

USD 43.99B
CTLT Catalent Inc

N/A

USD 10.78B
ELAN Elanco Animal Health

N/A

USD 6.18B
BHC Bausch Health Companies Inc

N/A

USD 3.60B
AMRX Amneal Pharmaceuticals, Inc. C..

N/A

USD 2.63B
CPHI China Pharma Holdings Inc

N/A

USD 4.03M
PRGO Perrigo Company PLC

N/A

N/A

ETFs Containing YCBD

PSY 0.00 % 0.76 %

N/A

N/A
MJUS Amplify ETF Trust 0.00 % 0.00 %

N/A

USD 0.15B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -45.19% 13% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -45.19% 13% F 3% F
Trailing 12 Months  
Capital Gain -55.81% 13% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -55.81% 13% F 3% F
Trailing 5 Years  
Capital Gain -99.69% 7% C- N/A F
Dividend Return N/A N/A N/A N/A N/A
Total Return -99.69% 7% C- N/A F
Average Annual (5 Year Horizon)  
Capital Gain -19.16% 20% F 4% F
Dividend Return -19.16% 20% F 3% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 168.48% 7% C- 4% F
Risk Adjusted Return -11.37% 40% F 19% F
Market Capitalization 2.14M 10% F 1% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector